Jerry J. Buccafusco – författare

The costs associated with a drug’s clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairment examines some of the most popular and successful animal archetypes used in the context of drug discovery. It provides integrated coverage of the latest research concerning neuronal systems relevant to cognitive function and dysfunction, assimilating reviews of this research within the context of each chapter. This approach is unique in that it brings together molecular and neurochemical methodologies, behavioral applications in translational models, and clinical applications. The book comprehensively discusses a wide variety of animal models of cognitive impairment, including genetic, lesion, pharmacological, and aging related impairments. It also explores the significance of this research in regards to the treatment of various addictions and disorders such as stroke, autism, Alzheimer’s, schizophrenia, and ADHD. Edited by two renowned authorities in the field, Animal Models of Cognitive Impairment is a timely book that provides integrated coverage of cutting-edge research that concerns neuronal systems relevant to cognitive function and dysfunction.

The costs associated with a drug’s clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairment examines some of the most popular and successful animal archetypes used in the context of drug discovery. It provides integrated coverage of the latest research concerning neuronal systems relevant to cognitive function and dysfunction, assimilating reviews of this research within the context of each chapter. This approach is unique in that it brings together molecular and neurochemical methodologies, behavioral applications in translational models, and clinical applications. The book comprehensively discusses a wide variety of animal models of cognitive impairment, including genetic, lesion, pharmacological, and aging related impairments. It also explores the significance of this research in regards to the treatment of various addictions and disorders such as stroke, autism, Alzheimer’s, schizophrenia, and ADHD. Edited by two renowned authorities in the field, Animal Models of Cognitive Impairment is a timely book that provides integrated coverage of cutting-edge research that concerns neuronal systems relevant to cognitive function and dysfunction.

The costs associated with a drug''s clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairmen

The costs associated with a drug''s clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairmen

Behavioral techniques used in animals to model human diseases and predict effects of novel drugs are as varied as the numbers of scientists who use them. Consequently, behavioral analysis is becoming an increasingly indispensable tool for the neuroscientist as information gained at the molecular and cellular level is put into practice in fully behaving animal subjects. Uses Animal Behavior Models to Examine Effects of Therapeutic Treatments on Human Cognition With contributions from more than 40 field specialists, Methods of Behavioral Analysis in Neuroscience reflects six years worth of updates to its first bestselling edition and elucidates new behavioral approaches that are quickly becoming field standards. This edition features new material on the relevance of transgenic mouse models for Alzheimer’s disease, behavioral methods for assessing the cognitive impairment associated with major psychotic disorders, the revival of the scopolamine reversal model for assessing the clinical relevance of AD drugs, and approaches to assessing cognitive impairment in aged mice. Each chapter presents theoretical background, methodology, and data interpretation, and many chapters include real-world examples of experiments that incorporate the models. With step-by-step, easy-to-reproduce methodologies, this sharply focused work covers well-studied behavioral approaches that provide a better understanding of the effects of disease and allow for better predictability of the effects of therapeutic treatments on the human cognition. It takes the guesswork out of designing the methodology for many of the most widely used animal behavioral approaches developed for the study of brain disorders, drug abuse, toxicology, and cognitive drug development.

During the past decade research into the pharmacology of cognition, particularly regarding learning and memory, has supported the concept that many potential neural targets exist for the development of cognitive-enhancing drugs. Whereas the main impetus for this research has been the ever growing population of individuals with dementing disorders such as Alzheimer`s disease, attention is also being focused on issues relating to cognitive impairment associated with "normal" aging. This book is useful as a source of information for making informed decisions regarding the relative utility and attributes of the various neural targets that have been studied to date.